BioCentury | Apr 28, 2020
Finance

Merck’s adjusted revenue guidance shows product mix matters during COVID-19

...for children over 24 months. Implantable fertility medicine Implanon/Nexplanon and surgical products such as Bridion sugammadex...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...vaccines business grew 17% at constant currencies in 2019, while sales of anesthesiology product Bridion sugammadex...
BioCentury | Jan 4, 2016
Finance

Big band swing

...inflammation in patients aged 12 and older Merck & Co. Inc. (NYSE:MRK) FDA approves Bridion sugammadex...
BioCentury | Dec 21, 2015
Clinical News

Bridion sugammadex regulatory update

...FDA approved Bridion sugammadex from Merck to reverse the effects of neuromuscular blockade induced by muscle...
...next month, at which time the pharma will disclose the drug’s price. FDA initially rejected Bridion...
...& Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Bridion sugammadex ( MK-8616 ) (formerly Org 25969 , SCH 900616...
BioCentury | Dec 15, 2015
Company News

FDA approves Merck's Bridion

...FDA approved Bridion sugammadex from Merck & Co. Inc. (NYSE:MRK) to reverse the effects of neuromuscular...
...cyclodextrin derivative in January, at which time it will disclose Bridion's price. FDA initially rejected Bridion...
...data. In November, FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 14-0 to support Bridion's...
BioCentury | Nov 5, 2015
Clinical News

FDA reviewers accept sugammadex data

...In sugammadex from Merck & Co. Inc. (NYSE:MRK), agency reviewers said the company has resolved the...
...FDA's Anesthetic and Analgesic Drug Products Advisory Committee will meet Friday to discuss the NDA. Sugammadex...
...for sugammadex expires in 2021. Its PDUFA date is Dec. 19. Merck markets sugammadex as Bridion...
BioCentury | Oct 5, 2015
Finance

Event planner

...myeloma (MM) patients undergoing autologous transplantation PDUFA date 10/23/15 Merck & Co. Inc. (NYSE:MRK) Bridion sugammadex...
BioCentury | Sep 28, 2015
Clinical News

Bridion sugammadex regulatory update

...Advisory Committee will meet on Nov. 6 to discuss an NDA from Merck for Bridion sugammadex...
...analyses on the data the pharma had submitted. The pharma markets the cyclodextrin derivative as Bridion...
...& Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Bridion sugammadex ( MK-8616 ) (formerly Org 25969 , SCH 900616...
BioCentury | May 4, 2015
Clinical News

Bridion sugammadex regulatory update

...FDA issued a complete response letter to Merck for an NDA for sugammadex to reverse neuromuscular...
...as Bridion outside the U.S. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Bridion sugammadex...
...Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Bridion sugammadex ( MK-8616 ) (formerly Org 25969 , SCH 900616...
BioCentury | Mar 30, 2015
Clinical News

Bridion sugammadex regulatory update

...March 18 meeting of its Anesthetic and Analgesic Drug Products Advisory Committee to discuss Merck’s sugammadex...
...“additional site inspections related to a hypersensitivity study.” FDA issued a not approvable letter for sugammadex...
...Inc . (NYSE:MRK), Whitehouse Station, N.J. Product: Bridion sugammadex ( MK-8616 ) (formerly Org 25969 , SCH 900616...
Items per page:
1 - 10 of 60